Form 4: Denali Therapeutics Director Erik Harris Reports Acquisition of Stock Options and Restricted Stock Units

Director Erik Harris reports acquisition of stock options and restricted stock units in Denali Therapeutics.

Summary

• On May 31, 2024, Erik Harris, a director of Denali Therapeutics Inc., reported the acquisition of 5,967 shares of common stock represented by Restricted Stock Units (RSUs) and a contingent right to receive one share of common stock.
• Harris also acquired 17,901 stock options with an exercise price of $18.56, exercisable starting May 31, 2024, and expiring on May 31, 2034.
• Following these transactions, Harris beneficially owns 17,052 shares of common stock, including 9,402 unvested RSUs, and 17,901 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it is a standard disclosure of insider transactions. The acquisition of shares and options suggests a positive outlook from the director, but it's not overtly bullish.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.

Future Outlook

The RSUs and stock options vest upon the earlier of one year from the grant date or the day preceding the next annual meeting of stockholders, incentivizing the director to contribute to the company's success.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding the director's stake in the company.
• The vesting schedule of the RSUs and stock options aligns the director's interests with those of the shareholders.

Key Dates